Trial Profile
Peg-INF alfa-2a plus ribavirin treatment of liver transplant patients with hepatitis C relaps on protocol liver biopsies - a Nordic study on rapid viral response, early viral response, end of treatment response and sustained viral response rates.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2013
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Erythropoietins
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Aug 2011 New trial record